From: The impact of frailty on survival in elderly intensive care patients with COVID-19: the COVIP study
Model 1 unadjusted HR (95% CI) | p value | Model 2 adjusted HR (95% CI) | p value | Model 3 adjusted HR (95% CI) | p value | |
---|---|---|---|---|---|---|
Survival at 30 days | ||||||
Vulnerable versus fit | 1.75 (1.35–2.25) | < 0.001 | 1.55 (1.14–2.10) | 0.011 | 1.14 (0.79–1.65) | 0.4811 |
Frail versus fit | 3.20 (2.56–4.13) | < 0.001 | 2.41 (1.77–3.27) | < 0.001 | 1.86 (1.36–2.52) | < 0.001 |
Treatment limitation | ||||||
Vulnerable versus fit | 2.26 (1.73–2.96) | < 0.001 | 1.7 (1.21–2.38) | 0.0021 | ||
Frail versus fit | 3.98 (3.08–5.21) | < 0.001 | 2.79 (1.96–3.91) | < 0.001 | ||
Mechanical ventilation | ||||||
Vulnerable versus fit | 0.83 (0.67–1.01) | 0.055 | 0.92 (0.73–1.16) | 0.5 | ||
Frail versus fit | 0.75 (0.62–0.92) | 0.005 | 0.69 (0.54–0.87) | 0.0043 | ||
Non-invasive ventilation | ||||||
Vulnerable versus fit | 1.58 (1.11–2.25) | 0.011 | 1.22 (0.79–1.88) | 0.37 | ||
Frail versus fit | 1.58 (1.12–2.24) | 0.009 | 1.26 (0.8–1.95) | 0.32 | ||
Non-invasive ventilation/mechanical ventilation | ||||||
Vulnerable versus fit | 0.94 (0.78–1.13) | 0.51 | 1 (0.81–1.24) | 0.99 | ||
Frail versus fit | 0.84 (0.7–1.02) | 0.069 | 0.74 (0.58–0.91) | 0.0096 | ||
Vasoactive drugs | ||||||
Vulnerable versus fit | 0.99 (0.81–1.22) | 0.93 | 1.09 (0.86–1.39) | 0.47 | ||
Frail versus fit | 1.01 (0.84–1.25) | 0.88 | 0.9 (0.7–1.15) | 0.44 | ||
Renal replacement therapy | ||||||
Vulnerable versus fit | 1.23 (0.81–1.86) | 0.33 | 1.14 (0.7–1.87) | 0.61 | ||
Frail versus fit | 1.62 (1.1–2.45) | 0.014 | 1.01 (0.59–1.65) | 0.98 |